Leishmanicidal and cytotoxic activities and 4D‐QSAR of 2‐arylidene indan‐1,3‐diones
The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2‐arylidene indan‐1,3‐diones is described. The compounds were evaluated against the leukemia cell lines...
Saved in:
Published in | Archiv der Pharmazie (Weinheim) Vol. 354; no. 10; pp. e2100081 - n/a |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2‐arylidene indan‐1,3‐diones is described. The compounds were evaluated against the leukemia cell lines HL60 and Nalm6, and the most effective ones were 2‐(4‐nitrobenzylidene)‐1H‐indene‐1,3(2H)‐dione (4) and 4‐[(1,3‐dioxo‐1H‐inden‐2(3H)‐ylidene)methyl]benzonitrile (10), presenting IC50 values of around 30 µmol/L against Nalm6. The leishmanicidal activity was assessed on Leishmania amazonensis, with derivative 4 (IC50 = 16.6 µmol/L) being the most active. A four‐dimensional quantitative structure–activity analysis (4D‐QSAR) was applied to the indandione derivatives, through partial least‐squares regression. The statistics presented by the regression models built with the selected field descriptors of Coulomb (C) and Lennard‐Jones (L) nature, considering the activities against L. amazonensis, HL60, and Nalm6 leukemia cells, were, respectively, R2 = 0.88, 0.92, and 0.98; Q2 = 0.83, 0.88, and 0.97. The presence of positive Coulomb descriptors near the carbonyl groups indicates that these polar groups are related to the activities. Besides, the presence of positive Lennard‐Jones descriptors close to substituents R3 or R1 indicates that bulky nonpolar substituents in these positions tend to increase the activities. This study provides useful insights into the mode of action of indandione derivatives for each biological activity involved.
The evaluation of 16 indan‐1,3‐dione derivatives against HL60 and Nalm6 cells revealed that, in general, the compounds were more effective against Nalm6 cells. The compounds were also assessed, for the first time, on Leishmania amazonensis. Four‐dimensional quantitative structure–activity models were developed for the evaluated activities. Useful insights into the mode of action of the indandione derivatives, for each biological activity involved, are described. |
---|---|
AbstractList | The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2‐arylidene indan‐1,3‐diones is described. The compounds were evaluated against the leukemia cell lines HL60 and Nalm6, and the most effective ones were 2‐(4‐nitrobenzylidene)‐1H‐indene‐1,3(2H)‐dione (4) and 4‐[(1,3‐dioxo‐1H‐inden‐2(3H)‐ylidene)methyl]benzonitrile (10), presenting IC50 values of around 30 µmol/L against Nalm6. The leishmanicidal activity was assessed on Leishmania amazonensis, with derivative 4 (IC50 = 16.6 µmol/L) being the most active. A four‐dimensional quantitative structure–activity analysis (4D‐QSAR) was applied to the indandione derivatives, through partial least‐squares regression. The statistics presented by the regression models built with the selected field descriptors of Coulomb (C) and Lennard‐Jones (L) nature, considering the activities against L. amazonensis, HL60, and Nalm6 leukemia cells, were, respectively, R2 = 0.88, 0.92, and 0.98; Q2 = 0.83, 0.88, and 0.97. The presence of positive Coulomb descriptors near the carbonyl groups indicates that these polar groups are related to the activities. Besides, the presence of positive Lennard‐Jones descriptors close to substituents R3 or R1 indicates that bulky nonpolar substituents in these positions tend to increase the activities. This study provides useful insights into the mode of action of indandione derivatives for each biological activity involved. Abstract The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2‐arylidene indan‐1,3‐diones is described. The compounds were evaluated against the leukemia cell lines HL60 and Nalm6, and the most effective ones were 2‐(4‐nitrobenzylidene)‐1 H ‐indene‐1,3(2 H )‐dione ( 4 ) and 4‐[(1,3‐dioxo‐1 H ‐inden‐2(3 H )‐ylidene)methyl]benzonitrile ( 10 ), presenting IC 50 values of around 30 µmol/L against Nalm6. The leishmanicidal activity was assessed on Leishmania amazonensis , with derivative 4 (IC 50 = 16.6 µmol/L) being the most active. A four‐dimensional quantitative structure–activity analysis (4D‐QSAR) was applied to the indandione derivatives, through partial least‐squares regression. The statistics presented by the regression models built with the selected field descriptors of Coulomb (C) and Lennard‐Jones (L) nature, considering the activities against L. amazonensis , HL60, and Nalm6 leukemia cells, were, respectively, R 2 = 0.88, 0.92, and 0.98; Q 2 = 0.83, 0.88, and 0.97. The presence of positive Coulomb descriptors near the carbonyl groups indicates that these polar groups are related to the activities. Besides, the presence of positive Lennard‐Jones descriptors close to substituents R 3 or R 1 indicates that bulky nonpolar substituents in these positions tend to increase the activities. This study provides useful insights into the mode of action of indandione derivatives for each biological activity involved. The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2‐arylidene indan‐1,3‐diones is described. The compounds were evaluated against the leukemia cell lines HL60 and Nalm6, and the most effective ones were 2‐(4‐nitrobenzylidene)‐1H‐indene‐1,3(2H)‐dione (4) and 4‐[(1,3‐dioxo‐1H‐inden‐2(3H)‐ylidene)methyl]benzonitrile (10), presenting IC50 values of around 30 µmol/L against Nalm6. The leishmanicidal activity was assessed on Leishmania amazonensis, with derivative 4 (IC50 = 16.6 µmol/L) being the most active. A four‐dimensional quantitative structure–activity analysis (4D‐QSAR) was applied to the indandione derivatives, through partial least‐squares regression. The statistics presented by the regression models built with the selected field descriptors of Coulomb (C) and Lennard‐Jones (L) nature, considering the activities against L. amazonensis, HL60, and Nalm6 leukemia cells, were, respectively, R2 = 0.88, 0.92, and 0.98; Q2 = 0.83, 0.88, and 0.97. The presence of positive Coulomb descriptors near the carbonyl groups indicates that these polar groups are related to the activities. Besides, the presence of positive Lennard‐Jones descriptors close to substituents R3 or R1 indicates that bulky nonpolar substituents in these positions tend to increase the activities. This study provides useful insights into the mode of action of indandione derivatives for each biological activity involved. The evaluation of 16 indan‐1,3‐dione derivatives against HL60 and Nalm6 cells revealed that, in general, the compounds were more effective against Nalm6 cells. The compounds were also assessed, for the first time, on Leishmania amazonensis. Four‐dimensional quantitative structure–activity models were developed for the evaluated activities. Useful insights into the mode of action of the indandione derivatives, for each biological activity involved, are described. The indan-1,3-dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the leishmanicidal and cytotoxicity evaluation of 16 2-arylidene indan-1,3-diones is described. The compounds were evaluated against the leukemia cell lines HL60 and Nalm6, and the most effective ones were 2-(4-nitrobenzylidene)-1H-indene-1,3(2H)-dione (4) and 4-[(1,3-dioxo-1H-inden-2(3H)-ylidene)methyl]benzonitrile (10), presenting IC values of around 30 µmol/L against Nalm6. The leishmanicidal activity was assessed on Leishmania amazonensis, with derivative 4 (IC = 16.6 µmol/L) being the most active. A four-dimensional quantitative structure-activity analysis (4D-QSAR) was applied to the indandione derivatives, through partial least-squares regression. The statistics presented by the regression models built with the selected field descriptors of Coulomb (C) and Lennard-Jones (L) nature, considering the activities against L. amazonensis, HL60, and Nalm6 leukemia cells, were, respectively, R = 0.88, 0.92, and 0.98; Q = 0.83, 0.88, and 0.97. The presence of positive Coulomb descriptors near the carbonyl groups indicates that these polar groups are related to the activities. Besides, the presence of positive Lennard-Jones descriptors close to substituents R or R indicates that bulky nonpolar substituents in these positions tend to increase the activities. This study provides useful insights into the mode of action of indandione derivatives for each biological activity involved. |
Author | Almeida Lima, Graziela D. Lima, Wallace P. Ferreira, Márcia M. C. Aguiar, Alex R. Bergmann, Bartira R. Borsodi, Maria P. G. Costa, Maria C. A. Teixeira, Róbson R. Souza, Ana P. M. Bressan, Gustavo C. |
Author_xml | – sequence: 1 givenname: Ana P. M. surname: Souza fullname: Souza, Ana P. M. organization: Universidade Federal de Viçosa – sequence: 2 givenname: Maria C. A. surname: Costa fullname: Costa, Maria C. A. organization: University of Campinas – sequence: 3 givenname: Alex R. surname: Aguiar fullname: Aguiar, Alex R. organization: Universidade Federal de Viçosa – sequence: 4 givenname: Gustavo C. surname: Bressan fullname: Bressan, Gustavo C. organization: Universidade do Grande Rio – sequence: 5 givenname: Graziela D. surname: Almeida Lima fullname: Almeida Lima, Graziela D. organization: Universidade Federal de Viçosa – sequence: 6 givenname: Wallace P. surname: Lima fullname: Lima, Wallace P. organization: Universidade Federal do Rio de Janeiro – sequence: 7 givenname: Maria P. G. surname: Borsodi fullname: Borsodi, Maria P. G. organization: Universidade Federal do Rio de Janeiro – sequence: 8 givenname: Bartira R. surname: Bergmann fullname: Bergmann, Bartira R. organization: Universidade Federal do Rio de Janeiro – sequence: 9 givenname: Márcia M. C. surname: Ferreira fullname: Ferreira, Márcia M. C. organization: University of Campinas – sequence: 10 givenname: Róbson R. orcidid: 0000-0003-3181-1108 surname: Teixeira fullname: Teixeira, Róbson R. email: robsonr.teixeira@ufv.br organization: Universidade Federal de Viçosa |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34323311$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkLtOAzEQRS0EIuHRUqKVaChI8Pix8ZYRbykS74pi5bUd4WjjDesNkI5P4Bv5EgYSgkRD4_HMHF9d3w2yGqrgCNkB2gVK2aGu7aTLKMOGKlghbZAMOgKUWCVtylPZSRnnLbIR4wgRTplcJy0uOE4B2uRh4Hx8HOvgjbe6THSwiZk1VVO9epNo0_hn33gXvxfi-OPt_fq2f5NUw4ThXdez0lsXXOKD1QEncMDxtB5dxi2yNtRldNuLuknuT0_ujs47g8uzi6P-oGN4j6NZRVPDWCZ4QVUhqbDCsoJZyV2aKip7RcEtBcdVBkwBDEWRgRHQw9ZmLOWbZH-uO6mrp6mLTT720biy1MFV05gzKVOuUDhDdO8POqqmdUB3SPUUSMUYRao7p0xdxVi7YT6p_Rg_mwPNv2LPv2LPl7Hjg92F7LQYO7vEf3JGIJsDL750s3_k8v7N8dWv-CejupCR |
CitedBy_id | crossref_primary_10_3390_v13112123 crossref_primary_10_1016_j_rechem_2023_101073 crossref_primary_10_4155_fmc_2023_0246 |
Cites_doi | 10.1016/j.ejmech.2019.111688 10.1093/qjmed/hct116 10.1016/j.ejmech.2018.02.037 10.1016/0022-1759(83)90303-4 10.3390/molecules24234411 10.2174/1389557518666180330101809 10.3390/molecules22050765 10.5306/wjco.v7.i1.54 10.29161/PT.v6.i2.2018.22 10.1002/cber.188702001137 10.1002/cem.1192 10.1016/S1359-6446(97)01079-9 10.7164/antibiotics.34.1402 10.1016/S0140-6736(18)31204-2 10.1002/minf.201000181 10.1039/C4OB02103G 10.3390/molecules25214890 10.1002/cem.1331 10.4061/2011/571242 10.1016/j.ejmech.2014.06.006 10.1590/S0100-40422013000400013 10.1016/j.drup.2004.07.002 10.1039/b508541a 10.2165/00139709-200524040-00005 10.1002/anie.201911530 10.1289/ehp.5758 10.7164/antibiotics.34.1389 10.1016/0223-5234(87)90054-7 10.1021/ci900014f 10.2174/1570179412666150817222851 10.1371/journal.pone.0035671 10.1016/j.biopha.2017.03.072 10.1080/14756360600958057 10.15171/apb.2017.041 10.3390/12051101 10.1016/j.taap.2018.08.012 10.1007/s11030-015-9589-z 10.1097/CAD.0000000000000944 10.1002/cem.3131 10.1016/j.ejmech.2017.03.078 10.3390/molecules18021881 10.3390/molecules201219857 10.7164/antibiotics.40.786 10.3390/molecules14072317 10.1016/j.pt.2003.09.008 10.1128/CMR.19.1.111-126.2006 10.1016/j.ejmech.2018.01.046 10.1016/j.tiv.2020.104777 10.1016/j.bmcl.2016.04.065 10.1007/s008940100045 10.1016/j.jcrpr.2017.07.001 10.1016/j.bmc.2016.06.027 10.1371/journal.pone.0134882 10.1016/j.tiv.2018.07.015 10.1016/j.dyepig.2017.07.009 10.3390/pathogens8040201 10.1590/S0103-50532002000600004 |
ContentType | Journal Article |
Copyright | 2021 Deutsche Pharmazeutische Gesellschaft 2021 Deutsche Pharmazeutische Gesellschaft. |
Copyright_xml | – notice: 2021 Deutsche Pharmazeutische Gesellschaft – notice: 2021 Deutsche Pharmazeutische Gesellschaft. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
DOI | 10.1002/ardp.202100081 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-4184 |
EndPage | n/a |
ExternalDocumentID | 10_1002_ardp_202100081 34323311 ARDP202100081 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23M 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABOCM ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACPOU ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA GWYGA H.T H.X HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 UB1 V2E W8V W99 WBFHL WBKPD WIH WIK WJL WOHZO WQJ WRC WUP WWP WXSBR WYISQ XG1 XV2 Y6R YCJ ZCG ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. 7X8 |
ID | FETCH-LOGICAL-c3731-4806c22943b08b504d4d2b2d53e668057bb3d01e38912811f4b91c417912d9263 |
IEDL.DBID | DR2 |
ISSN | 0365-6233 |
IngestDate | Sat Aug 17 00:45:18 EDT 2024 Thu Oct 10 15:41:08 EDT 2024 Fri Aug 23 01:30:29 EDT 2024 Sat Sep 28 08:22:35 EDT 2024 Sat Aug 24 00:59:57 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | 2-arylidene indan-1,3-diones cytotoxic activity leishmanicidal activity indan-1,3-dione 4D-QSAR |
Language | English |
License | 2021 Deutsche Pharmazeutische Gesellschaft. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3731-4806c22943b08b504d4d2b2d53e668057bb3d01e38912811f4b91c417912d9263 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3181-1108 |
PMID | 34323311 |
PQID | 2578158220 |
PQPubID | 866361 |
PageCount | 16 |
ParticipantIDs | proquest_miscellaneous_2556385049 proquest_journals_2578158220 crossref_primary_10_1002_ardp_202100081 pubmed_primary_34323311 wiley_primary_10_1002_ardp_202100081_ARDP202100081 |
PublicationCentury | 2000 |
PublicationDate | October 2021 2021-Oct 2021-10-00 20211001 |
PublicationDateYYYYMMDD | 2021-10-01 |
PublicationDate_xml | – month: 10 year: 2021 text: October 2021 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Frankfurt |
PublicationTitle | Archiv der Pharmazie (Weinheim) |
PublicationTitleAlternate | Arch Pharm (Weinheim) |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 1887; 20 2017; 7 2017; 4 2004; 7 2002; 13 2020; 59 2018; 41 1997; 2 2003; 19 2003; 111 2009; 49 2005; 24 2013; 18 2018; 6 2009; 14 2021; 32 1987; 40 2010; 24 2000 2013; 12 2019; 24 1983; 65 2014; 13 2007; 22 1981; 34 2019; 8 2009; 23 2015; 14 2015; 5 2011 2018; 149 2019; 30 2015; 94 2017; 22 2018; 146 2015; 10 2007 2006; 19 2020; 34 2017; 134 2007; 12 2019; 183 2016; 13 2012; 31 2014; 107 2011; 2011 2018; 18 1987; 22 2016; 7 2017; 90 2013; 36 2018; 392 2020; 31 2019; 42 2001; 7 2018; 356 2016; 20 2005; 7 2020; 25 2016 2015 2020; 65 2012; 7 2009; 1 2017; 147 2018; 53 2016; 26 2016; 24 e_1_2_7_5_1 Cambridge Crystallographic Data Centre (e_1_2_7_63_1) 2007 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_60_1 e_1_2_7_17_1 Dias M. C. F. (e_1_2_7_36_1) 2021; 32 e_1_2_7_62_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_64_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_45_1 e_1_2_7_68_1 e_1_2_7_47_1 Lima A. M. A. (e_1_2_7_35_1) 2019; 42 e_1_2_7_49_1 e_1_2_7_28_1 Teixeira R. R. (e_1_2_7_34_1) 2019; 30 Monzote L. (e_1_2_7_11_1) 2009; 1 Gazolla P. A. R. (e_1_2_7_37_1) 2018; 41 Wellington K. W. (e_1_2_7_61_1) 2015; 5 e_1_2_7_50_1 e_1_2_7_71_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_21_1 e_1_2_7_56_1 Guidance Document on the Validation of (Quantitative) Structure‐Activity Relationship [(Q)SAR] Models (e_1_2_7_55_1) 2007 e_1_2_7_58_1 e_1_2_7_39_1 e_1_2_7_6_1 Jeyachandran M. (e_1_2_7_26_1) 2011 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 WHO (e_1_2_7_4_1) 2015 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_65_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_67_1 e_1_2_7_48_1 e_1_2_7_69_1 Amidi S. (e_1_2_7_23_1) 2013; 12 e_1_2_7_27_1 e_1_2_7_29_1 Nielsen A. B. (e_1_2_7_66_1) 2000 e_1_2_7_72_1 e_1_2_7_51_1 e_1_2_7_70_1 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_22_1 e_1_2_7_57_1 e_1_2_7_20_1 e_1_2_7_59_1 e_1_2_7_38_1 |
References_xml | – volume: 19 start-page: 502 year: 2003 publication-title: Trends Parasitol. – volume: 5 year: 2015 publication-title: Chem. Soc. Rev. – volume: 4 start-page: 127 year: 2017 publication-title: J. Cancer Res. Pract. – volume: 24 start-page: 4411 year: 2019 publication-title: Molecules – volume: 7 start-page: 306 year: 2001 publication-title: J. Mol. Mod. – volume: 7 start-page: 3297 year: 2005 publication-title: Phys. Chem. Chem. Phys. – volume: 7 year: 2012 publication-title: PLoS One – volume: 34 start-page: 1402 year: 1981 publication-title: J. Antibiot. – volume: 90 start-page: 375 year: 2017 publication-title: Biomed. Pharmacother. – volume: 12 start-page: 91 year: 2013 publication-title: Iran. J. Pharm. Sci. – volume: 7 start-page: 339 year: 2017 publication-title: Adv. Pharm. Bull. – volume: 7 start-page: 257 year: 2004 publication-title: Drug Resist. Updates – volume: 24 start-page: 681 year: 2010 publication-title: J. Chemom. – volume: 32 start-page: 572 year: 2021 publication-title: J. Braz. Chem. Soc. – volume: 20 start-page: 589 year: 1887 publication-title: Ber. Dtsch. Chem. Ges. – volume: 53 start-page: 1 year: 2018 publication-title: Toxicol. In Vitro – volume: 19 start-page: 111 year: 2006 publication-title: Clin. Microbiol. Rev. – volume: 22 start-page: 765 year: 2017 publication-title: Molecules – volume: 183 year: 2019 publication-title: Eur. J. Med. Chem. – volume: 14 year: 2015 publication-title: Molecules – volume: 23 start-page: 32 year: 2009 publication-title: J. Chemom. – volume: 13 start-page: 601 year: 2014 publication-title: Org. Biomol. Chem. – volume: 59 start-page: 221 year: 2020 publication-title: Angew. Chem. Int. Ed. – volume: 94 start-page: 509 year: 2015 publication-title: Eur. J. Med. Chem. – volume: 40 start-page: 786 year: 1987 publication-title: J. Antibiot. – volume: 14 start-page: 2317 year: 2009 publication-title: Molecules – volume: 42 start-page: 473 year: 2019 publication-title: Quim. Nova – volume: 65 start-page: 55 year: 1983 publication-title: J. Immunol. Methods – volume: 22 start-page: 229 year: 1987 publication-title: Eur. J. Med. Chem. – volume: 30 start-page: 541 year: 2019 publication-title: J. Braz. Chem. Soc. – year: 2015 – volume: 25 start-page: 4890 year: 2020 publication-title: Molecules – volume: 8 start-page: 201 year: 2019 publication-title: Pathogens – volume: 147 start-page: 50 year: 2017 publication-title: Dyes Pigm. – volume: 392 start-page: 951 year: 2018 publication-title: Lancet – volume: 49 start-page: 1428 year: 2009 publication-title: J. Chem. Inf. Model. – volume: 134 start-page: 97 year: 2017 publication-title: Eur. J. Med. Chem. – volume: 13 start-page: 742 year: 2002 publication-title: J. Braz. Chem. Soc. – volume: 24 start-page: 259 year: 2005 publication-title: Toxicol. Rev. – year: 2007 – volume: 13 start-page: 385 year: 2016 publication-title: Curr. Org. Synth. – volume: 111 start-page: 1361 year: 2003 publication-title: Environ. Health Persp. – volume: 18 start-page: 1321 year: 2018 publication-title: Mini‐Rev. Org. Chem. – volume: 41 start-page: 497 year: 2018 publication-title: Quim. Nova – year: 2000 – volume: 20 start-page: 111 year: 2016 publication-title: Mol. Divers. – volume: 12 start-page: 1101 year: 2007 publication-title: Molecules – volume: 34 year: 2020 publication-title: J. Chemom. – volume: 2 start-page: 457 year: 1997 publication-title: Drug Discov. Today – volume: 107 start-page: 7 year: 2014 publication-title: QJM – volume: 2011 year: 2011 publication-title: Mol. Biol. Int. – volume: 22 start-page: 37 year: 2007 publication-title: J. Enzyme Inhib. Med. Chem. – year: 2016 – volume: 1 start-page: 9 year: 2009 publication-title: Open Antimicrob. Agents J. – volume: 65 year: 2020 publication-title: Toxicol. In Vitro – volume: 31 start-page: 718 year: 2020 publication-title: Anticancer Drugs – volume: 10 year: 2015 publication-title: PLoS One – volume: 18 start-page: 1881 year: 2013 publication-title: Molecules – volume: 146 start-page: 274 year: 2018 publication-title: Eur. J. Med. Chem. – volume: 356 start-page: 214 year: 2018 publication-title: Toxicol. Appl. Pharmacol. – volume: 31 start-page: 75 year: 2012 publication-title: Mol. Inf. – volume: 6 start-page: 22 year: 2018 publication-title: PharmaTutor – volume: 149 start-page: 98 year: 2018 publication-title: Eur. J. Med. Chem. – volume: 34 start-page: 1389 year: 1981 publication-title: J. Antibiot. – volume: 24 start-page: 3829 year: 2016 publication-title: Bioorg. Med. Chem. – year: 2011 publication-title: Org. Chem. Int. – volume: 7 start-page: 54 year: 2016 publication-title: World J. Clin. Oncol. – volume: 26 start-page: 2810 year: 2016 publication-title: Bioorg. Med. Chem. Lett. – volume: 36 start-page: 554 year: 2013 publication-title: Quim. Nova – ident: e_1_2_7_45_1 doi: 10.1016/j.ejmech.2019.111688 – ident: e_1_2_7_7_1 doi: 10.1093/qjmed/hct116 – ident: e_1_2_7_31_1 doi: 10.1016/j.ejmech.2018.02.037 – ident: e_1_2_7_62_1 doi: 10.1016/0022-1759(83)90303-4 – ident: e_1_2_7_50_1 doi: 10.3390/molecules24234411 – ident: e_1_2_7_20_1 doi: 10.2174/1389557518666180330101809 – ident: e_1_2_7_28_1 doi: 10.3390/molecules22050765 – volume: 32 start-page: 572 year: 2021 ident: e_1_2_7_36_1 publication-title: J. Braz. Chem. Soc. contributor: fullname: Dias M. C. F. – year: 2011 ident: e_1_2_7_26_1 publication-title: Org. Chem. Int. contributor: fullname: Jeyachandran M. – ident: e_1_2_7_13_1 doi: 10.5306/wjco.v7.i1.54 – ident: e_1_2_7_59_1 doi: 10.29161/PT.v6.i2.2018.22 – ident: e_1_2_7_15_1 doi: 10.1002/cber.188702001137 – ident: e_1_2_7_72_1 doi: 10.1002/cem.1192 – ident: e_1_2_7_69_1 doi: 10.1016/S1359-6446(97)01079-9 – ident: e_1_2_7_30_1 doi: 10.7164/antibiotics.34.1402 – ident: e_1_2_7_2_1 doi: 10.1016/S0140-6736(18)31204-2 – ident: e_1_2_7_70_1 doi: 10.1002/minf.201000181 – ident: e_1_2_7_49_1 doi: 10.1039/C4OB02103G – ident: e_1_2_7_53_1 doi: 10.3390/molecules25214890 – volume: 42 start-page: 473 year: 2019 ident: e_1_2_7_35_1 publication-title: Quim. Nova contributor: fullname: Lima A. M. A. – ident: e_1_2_7_57_1 doi: 10.1002/cem.1331 – volume: 5 year: 2015 ident: e_1_2_7_61_1 publication-title: Chem. Soc. Rev. contributor: fullname: Wellington K. W. – ident: e_1_2_7_5_1 doi: 10.4061/2011/571242 – ident: e_1_2_7_21_1 doi: 10.1016/j.ejmech.2014.06.006 – volume-title: GaussView 3.0 User's Reference year: 2000 ident: e_1_2_7_66_1 contributor: fullname: Nielsen A. B. – ident: e_1_2_7_71_1 doi: 10.1590/S0100-40422013000400013 – ident: e_1_2_7_10_1 doi: 10.1016/j.drup.2004.07.002 – ident: e_1_2_7_64_1 doi: 10.1039/b508541a – ident: e_1_2_7_65_1 – ident: e_1_2_7_22_1 doi: 10.2165/00139709-200524040-00005 – ident: e_1_2_7_17_1 doi: 10.1002/anie.201911530 – ident: e_1_2_7_56_1 doi: 10.1289/ehp.5758 – ident: e_1_2_7_29_1 doi: 10.7164/antibiotics.34.1389 – ident: e_1_2_7_24_1 doi: 10.1016/0223-5234(87)90054-7 – ident: e_1_2_7_67_1 doi: 10.1021/ci900014f – ident: e_1_2_7_18_1 doi: 10.2174/1570179412666150817222851 – ident: e_1_2_7_3_1 doi: 10.1371/journal.pone.0035671 – ident: e_1_2_7_52_1 doi: 10.1016/j.biopha.2017.03.072 – ident: e_1_2_7_48_1 doi: 10.1080/14756360600958057 – volume-title: OECD Environment Health and Safety Publications Series on Testing and Assessment No. 69 year: 2007 ident: e_1_2_7_55_1 contributor: fullname: Guidance Document on the Validation of (Quantitative) Structure‐Activity Relationship [(Q)SAR] Models – ident: e_1_2_7_14_1 doi: 10.15171/apb.2017.041 – volume-title: Leishmaniasis Fact Sheet No. 375 year: 2015 ident: e_1_2_7_4_1 contributor: fullname: WHO – ident: e_1_2_7_44_1 doi: 10.3390/12051101 – ident: e_1_2_7_39_1 doi: 10.1016/j.taap.2018.08.012 – ident: e_1_2_7_19_1 doi: 10.1007/s11030-015-9589-z – volume: 30 start-page: 541 year: 2019 ident: e_1_2_7_34_1 publication-title: J. Braz. Chem. Soc. contributor: fullname: Teixeira R. R. – volume-title: Cambridge Structural Database Software Version 5.29‐2007 + 1 Update year: 2007 ident: e_1_2_7_63_1 contributor: fullname: Cambridge Crystallographic Data Centre – ident: e_1_2_7_33_1 doi: 10.1097/CAD.0000000000000944 – ident: e_1_2_7_60_1 doi: 10.1002/cem.3131 – ident: e_1_2_7_40_1 doi: 10.1016/j.ejmech.2017.03.078 – ident: e_1_2_7_43_1 doi: 10.3390/molecules18021881 – ident: e_1_2_7_47_1 doi: 10.3390/molecules201219857 – ident: e_1_2_7_27_1 doi: 10.7164/antibiotics.40.786 – ident: e_1_2_7_6_1 doi: 10.3390/molecules14072317 – volume: 41 start-page: 497 year: 2018 ident: e_1_2_7_37_1 publication-title: Quim. Nova contributor: fullname: Gazolla P. A. R. – ident: e_1_2_7_9_1 doi: 10.1016/j.pt.2003.09.008 – ident: e_1_2_7_58_1 doi: 10.3390/molecules24234411 – volume: 12 start-page: 91 year: 2013 ident: e_1_2_7_23_1 publication-title: Iran. J. Pharm. Sci. contributor: fullname: Amidi S. – ident: e_1_2_7_8_1 doi: 10.1128/CMR.19.1.111-126.2006 – ident: e_1_2_7_46_1 doi: 10.1016/j.ejmech.2018.01.046 – ident: e_1_2_7_32_1 doi: 10.1016/j.tiv.2020.104777 – ident: e_1_2_7_41_1 doi: 10.1016/j.bmcl.2016.04.065 – ident: e_1_2_7_68_1 doi: 10.1007/s008940100045 – ident: e_1_2_7_12_1 doi: 10.1016/j.jcrpr.2017.07.001 – ident: e_1_2_7_25_1 doi: 10.1016/j.bmc.2016.06.027 – ident: e_1_2_7_42_1 doi: 10.1371/journal.pone.0134882 – volume: 1 start-page: 9 year: 2009 ident: e_1_2_7_11_1 publication-title: Open Antimicrob. Agents J. contributor: fullname: Monzote L. – ident: e_1_2_7_38_1 doi: 10.1016/j.tiv.2018.07.015 – ident: e_1_2_7_16_1 doi: 10.1016/j.dyepig.2017.07.009 – ident: e_1_2_7_51_1 doi: 10.3390/pathogens8040201 – ident: e_1_2_7_54_1 doi: 10.1590/S0103-50532002000600004 |
SSID | ssj0003025 |
Score | 2.3453095 |
Snippet | The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the... The indan-1,3-dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the... Abstract The indan‐1,3‐dione and its derivatives are important building blocks in organic synthesis and present important biological activities. Herein, the... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e2100081 |
SubjectTerms | 2‐arylidene indan‐1,3‐diones 4D‐QSAR Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antiprotozoal Agents - chemical synthesis Antiprotozoal Agents - chemistry Antiprotozoal Agents - pharmacology Cell Line, Tumor cytotoxic activity HL-60 Cells Humans Indans - chemical synthesis Indans - chemistry Indans - pharmacology indan‐1,3‐dione Inhibitory Concentration 50 Leishmania mexicana - drug effects leishmanicidal activity Leukemia Leukemia - drug therapy Quantitative Structure-Activity Relationship |
Title | Leishmanicidal and cytotoxic activities and 4D‐QSAR of 2‐arylidene indan‐1,3‐diones |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fardp.202100081 https://www.ncbi.nlm.nih.gov/pubmed/34323311 https://www.proquest.com/docview/2578158220 https://search.proquest.com/docview/2556385049 |
Volume | 354 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEF6hnHqhUGhJoWiRUHrJY1927GNEQAhBlQaQkDhY3kfUqJWDsINIT_0J_Y38Embs2G7ooRK9WGuvvd7d2Z2Z3Z35hpBD4dnA90PTYSaABYoUvBNrYIbo1GljDxGk0FH44ot_eq3ObrybP7z4C3yIasMNZ0bOr3GCxzrt1aCh0IGINyl4LtaACXPZR5uu4bjGj5Isj7rK0JQL5LwsURuZ6K1-viqV_lI1VzXXXPScvCVxWenC4uR7d57prvn5As_xf1q1QdaXeikdFANpk6y55B1pjQpg60WbXtV-WmmbtuiohrxebJHbczdNvyGUhplaKCZOLDWLbJbNHqeGou_EQ47cmmeo4dOv318vB2M6m1ABaajtD4xt6ihuECTwhLclXC2iKKXb5Prk-OrotLMM29Axsi-B4AHzjRChkpoF2mPKKiu0sJ50vh-Afqi1tIw7PCEVAecTpUNuMBIaFzYUvnxPGgmUv0OoUJoJE1pYd02UDGzgVAwKXl9Z7XxmJk3yuSRbdFegc0QFDrOIsCejqiebZK-karScpWmE7Ip7oCKxJjmosmF-4aFJnLjZHN_xgEVBK8Im-VCMhupX6JQrJYfCRU7Tf9QhGoyHo-ru42s-2iVvMF1YE-6RRnY_d59AK8r0fj7ynwF5LgOR |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VcoBLy7OkLWWRULkk7b7s2seItAqQViGkEhIHy_uIiFo5VeNUDSd-Ar-RX8KMHTtKOSDBxbJ37fW-5rG7M98AvJGBi8Iwti1uI1ygKClaqUFmSE6dLg0IQYochU_Pwu65_vAlqKwJyRemxIeoN9yIMgp-TQROG9KHS9RQ7EECnJSikGv34D7SvKLoDZ3BEkFK8SLuKidjLpT0qsJt5PJw9ftVufSHsrmquxbC52QTTFXt0ubk4mCWmwP7_Q6i43-16xFsLFRT1i7n0mNY89kT2O-X2NbzJhsuXbWmTbbP-kvU6_lT-Nrz4-k3QtOwY4fFpJljdp5P8snt2DJyn7gpwFuLDN359ePnp8_tAZuMmMR7rO4lhTf1jPYIMkwRTYVXR0BK02dwfnI8fNdtLSI3tKw6UjjmEQ-tlLFWhkcm4NppJ410gfJhGKGKaIxyXHg6JJWRECNtYmEpGJqQLpaheg7rGZb_ApjUhksbO1x6jbSKXOR1ijrekXbGh9yOGvC2GrfkqgToSEooZplQTyZ1TzZgtxrWZEGo04Q4lghQS-INeF1nI4nRuUma-cmM3gmQS2Er4gZsldOh_hX55SolsHBZDOpf6pC0B51-_bT9Lx-9ggfd4Wkv6b0_-7gDDym9NC7chfX8euZfopKUm72CDH4DqC0HqQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB5BkRAX3pTQAouEyiVp9-WtfYwaogKlCqGVKnGwvA-LiMqpGqdqeuIn8Bv5JZ2xE4fAAQkulr1rr3d3dna_fcw3AK9l5GNjEtfhLsYJipKik1nsDMmo02cRMUiRofDHQ7N_rN-fRCe_WPHX_BDNghtpRtVfk4Kf-XxnSRqKFUh8k1JUw9pNuKUNwl-CRcMlgZTildtVTme5cKBXC9pGLndWv18dlv7AmqvQtRp7-vcgW-S6PnLybXta2m139Ruh4_8U6z7cnQNT1q1b0gO4EYqHsDWoma1nbXa0NNSatNkWGyw5r2eP4MtBGE2-EpeGG3lMJis8c7NyXI4vR46R8cRFRd1aRejez-8_Pn3uDtk4ZxLvMben5Nw0MFohKDBEtBVePdEoTR7Dcf_t0d5-Z-63oePUrkKJx9w4KROtLI9txLXXXlrpIxWMiREgWqs8F4G2SGUsRK5tIhy5QhPSJ9KoJ7BWYPpPgUltuXSJx4lXrlXs46AzRHi72ttguMtb8GYhtvSspudIayJmmVJNpk1NtmBzIdV0rqaTlPorESFG4i141USjgtGuSVaE8ZTeibCPwlIkLVivW0PzK7LKVUpg4rKS6V_ykHaHvUHz9OxfPnoJtwe9fnrw7vDDBtyh4Ppk4SaslefT8BwRUmlfVEpwDYcZBlg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Leishmanicidal+and+cytotoxic+activities+and+4D-QSAR+of+2-arylidene+indan-1%2C3-diones&rft.jtitle=Archiv+der+Pharmazie+%28Weinheim%29&rft.au=de+Souza%2C+Ana+P+M&rft.au=Costa%2C+Maria+C+A&rft.au=de+Aguiar%2C+Alex+R&rft.au=Bressan%2C+Gustavo+C&rft.date=2021-10-01&rft.eissn=1521-4184&rft.volume=354&rft.issue=10&rft.spage=e2100081&rft_id=info:doi/10.1002%2Fardp.202100081&rft_id=info%3Apmid%2F34323311&rft.externalDocID=34323311 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0365-6233&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0365-6233&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0365-6233&client=summon |